BAX (Baxter International) Debt-to-Equity : 1.46 (As of Mar. 2025)

View and export this data going back to 1961. Start your Free Trial

What is Baxter International Debt-to-Equity?

Baxter International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $662 Mil. Baxter International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $9,647 Mil. Baxter International's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $7,081 Mil. Baxter International's debt to equity for the quarter that ended in Mar. 2025 was 1.46.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Baxter International's Debt-to-Equity or its related term are showing as below:

BAX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.32 Med: 0.78 Max: 3.05
Current: 1.46

During the past 13 years, the highest Debt-to-Equity Ratio of Baxter International was 3.05. The lowest was 0.32. And the median was 0.78.

BAX's Debt-to-Equity is ranked worse than
92.11% of 697 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs BAX: 1.46

Baxter International Debt-to-Equity Historical Data

The historical data trend for Baxter International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baxter International Debt-to-Equity Chart

Baxter International Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.78

2.02

2.95

1.68

1.93

Baxter International Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Equity	Get a 7-Day Free Trial															1.73	1.75	1.68	1.93	1.46

Competitive Comparison of Baxter International's Debt-to-Equity

For the Medical Instruments & Supplies subindustry, Baxter International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Baxter International's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Baxter International's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Baxter International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Baxter International's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2832	+	10617)	/	6964
	=	1.93

Baxter International's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(662	+	9647)	/	7081
	=	1.46

Baxter International (NYSE:BAX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Baxter International Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Baxter International's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Baxter International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baxter International Inc (NYSE:BAX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BAX:Mexico 1BAX:Italy 0QK8:UK BTL:Germany BTL:Germany B1AX34:Brazil BAX:Austria

Address

One Baxter Parkway, Deerfield, IL, USA, 60015

Website

https://www.baxter.com

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Executives

Jeanne K Mason	officer: CVP, Human Resources	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Joel T. Grade	officer: EVP, Chief Financial Officer	SYSCO CORPORATION, 1390 ENCLAVE PARKWAY, HOUSTON TX 77077
Stephen H Rusckowski	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ampofo William A. Ii	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Christopher A. Toth	officer: EVP, Group Pres, Kidney Care	1252 COOLIDGE AVE., SAN JOSE CA 95125
Stroucken Albert P L	director	BAXTER INTERNATIONAL INC., ONE BAXTER PARKWAY, DEERFIELD IL 60015
Reaz Rasul	officer: EVP, Group Pres, Healthcare	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Alok Sonig	officer: EVP, Group President, Pharm	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Heather Knight	officer: EVP, Group Pres, Medical	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Jacqueline Kunzler	officer: SVP, Chief Quality Officer	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Steven Flynn	officer: SVP, President, APAC	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Peter M Wilver	director
David Brent Shafer	director	2800 ROCKCREEK PARKWAY, NORTH KANSAS CITY MO 64117
Cathy R Smith	director	TARGET CORPORATION, 1000 NICOLLET MALL, TPS-3155, MINNEAPOLIS MN 55403
Patricia Morrison	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015